The Colon Cancer Alliance recognizes that there is a growing disconnect between drug development, which is increasingly personalized and the various reimbursement models which are increasingly “one size fits all” as a way to control costs. The Alliance supports reimbursement models that help make treatments for colorectal cancer more accessible and affordable, but we oppose those that do so at the expense of innovation.  Above all, we believe each patient is unique and this must be recognized both in the treatment decisions and in how we pay for that treatment.  Our advocacy efforts currently focus on:

  • CMMI proposed rule change to Medicare Part B
  • The various Value Framework proposals
  • Formula tiering / co-insurance issue
  • Health insurance exchange market, including greater transparency
  • Biosimilars

We are committed to increasing the screen rate and we support initiatives that improve access to and quality of colonoscopies, as well as access to alternative screening methods for adults that cannot or will not have a colonoscopy. Colorectal cancer can be largely prevented with timely screening, yet a third of at-risk adults have not taken this potentially lifesaving step.  Our advocacy efforts currently focus on:

  • Colonoscopy Quality Control Measures
  • Closing the Medicare Colonoscopy Loophole
  • USPSTF final recommendations on DNA stool test and CT Colonography
  • Obtaining HEDIS measure for DNA stool test
  • Ensuring coverage for DNA blood test

Let your voice be heard! Speak Up, Speak Out is our advocacy series where we bring you the news and information you need to know every third Tuesday of the month.

staff_Eric HargisAbout the Author

Mr. Eric Hargis, Executive Management Consultant, joined the Colon Cancer Alliance as CEO in January 2014. He has more than 35 years of relevant leadership experience in national health organizations and has a proven track record of supporting key advocacy issues that matter to the community. 

Our advocacy efforts are made possible in part by: